{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T07:30:50Z","timestamp":1787643050391,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Osimertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, was developed to overcome resistance from EGFR-mutant non\u2013small-cell lung cancer (NSCLC). While it offers significant therapeutic benefits, reports have linked Osimertinib to cardiotoxic effects. This study aims to clarify the direct cardiotoxicity of Osimertinib by reviewing clinical trials and cohort studies involving Osimertinib monotherapy compared to other EGFR inhibitors. A search was conducted in online databases. Measured outcomes included risk of heart failure (HF), myocardial infarction (MI), decline in left ventricular ejection fraction (LVEF), arrhythmias, and pericardial effusion. These outcomes were reported as risk ratio (RR) with a random effects model using 95% confidence intervals (CI). Five studies with 19,008 patients (age 68\u2009\u00b1\u200913, 65% female) were selected. Osimertinib therapy was associated with an increased risk of HF (RR\u2009=\u20091.45, 95% CI 1.19\u20131.76,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0002), decline in LVEF (RR\u2009=\u20093.10, 95% CI 1.72\u20135.59,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0002) and MI (RR\u2009=\u20091.40, 95% CI 1.09\u20131.79,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.0078) compared to other EGFR inhibitors. There was no difference in the risk of arrhythmias and pericardial effusion. Osimertinib therapy is associated with an increased risk of HF and a decline in LVEF compared to other EGFR inhibitors, while associations with MI and arrhythmias were less consistent. Although these events are infrequent, their potential severity warrants proactive cardiac monitoring for patients receiving Osimertinib, particularly in patients with pre-existing risk factors.\n                  <\/jats:p>","DOI":"10.1007\/s12012-026-10106-x","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:32:25Z","timestamp":1773034345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cardiotoxic Effects of Osimertinib Compared to Other EGFR Inhibitors: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-347X","authenticated-orcid":false,"given":"Alan","family":"Garcia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mueez Alam","family":"Kayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Alejandro","family":"Navarro-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky E.","family":"Lemus-Zamora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Salama-Frisbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Fretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Tellez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aviles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"issue":"10066","key":"10106_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S0140-6736(16)30958-8","volume":"389","author":"FR Hirsch","year":"2017","unstructured":"Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J. Jr., Wu, Y. L., et al. (2017). Lung cancer: current therapies and new targeted treatments. Lancet, 389(10066), 299\u2013311.","journal-title":"Lancet"},{"key":"10106_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","volume":"139","author":"R Roskoski","year":"2019","unstructured":"Roskoski, R. (2019). Jr. Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers. Pharmacological Research, 139, 395\u2013411.","journal-title":"Pharmacological Research"},{"issue":"Suppl 1","key":"10106_CR3","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","volume":"7","author":"B Burtness","year":"2009","unstructured":"Burtness, B., Anadkat, M., Basti, S., Hughes, M., Lacouture, M. E., McClure, J. S., et al. (2009). NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. Journal Of The National Comprehensive Cancer Network, 7(Suppl 1), S5\u201321. quiz S2\u20134.","journal-title":"Journal Of The National Comprehensive Cancer Network"},{"key":"10106_CR4","doi-asserted-by":"crossref","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, J\u00e4nne PA, Kocher O, Meyerson M, et al. EGFRMutation and Resistance of Non\u2013Small-Cell Lung Cancer to Gefitinib. New England Journal of Medicine. 2005;352(8):786\u201392.","DOI":"10.1056\/NEJMoa044238"},{"issue":"9","key":"10106_CR5","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/2159-8290.CD-14-0337","volume":"4","author":"DA Cross","year":"2014","unstructured":"Cross, D. A., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., et al. (2014). AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discovery, 4(9), 1046\u20131061.","journal-title":"Cancer Discovery"},{"issue":"7","key":"10106_CR6","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok, T. S., Wu, Y. L., Ahn, M. J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., et al. (2017). Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. New England Journal Of Medicine, 376(7), 629\u2013640.","journal-title":"New England Journal Of Medicine"},{"issue":"1","key":"10106_CR7","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., et al. (2020). Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. New England Journal Of Medicine, 382(1), 41\u201350.","journal-title":"New England Journal Of Medicine"},{"issue":"2","key":"10106_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., et al. (2018). Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. New England Journal Of Medicine, 378(2), 113\u2013125.","journal-title":"New England Journal Of Medicine"},{"issue":"16","key":"10106_CR9","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1056\/NEJMoa2403614","volume":"391","author":"BC Cho","year":"2024","unstructured":"Cho, B. C., Lu, S., Felip, E., Spira, A. I., Girard, N., Lee, J. S., et al. (2024). Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. New England Journal Of Medicine, 391(16), 1486\u20131498.","journal-title":"New England Journal Of Medicine"},{"issue":"5","key":"10106_CR10","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","volume":"8","author":"SA Crone","year":"2002","unstructured":"Crone, S. A., Zhao, Y. Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002). ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Medicine, 8(5), 459\u2013465.","journal-title":"Nature Medicine"},{"issue":"7","key":"10106_CR11","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1002\/cncr.10854","volume":"95","author":"DL Keefe","year":"2002","unstructured":"Keefe, D. L. (2002). Trastuzumab-associated cardiotoxicity. Cancer, 95(7), 1592\u20131600.","journal-title":"Cancer"},{"issue":"2","key":"10106_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","volume":"138","author":"K Bersell","year":"2009","unstructured":"Bersell, K., Arab, S., Haring, B., & K\u00fchn, B. (2009). Neuregulin1\/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell, 138(2), 257\u2013270.","journal-title":"Cell"},{"key":"10106_CR13","doi-asserted-by":"publisher","first-page":"1404692","DOI":"10.3389\/fphar.2024.1404692","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X., Lin, Y., Lin, S., Huang, J., & Ruan, Z. (2024). Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond. Frontiers In Pharmacology, 15, 1404692.","journal-title":"Frontiers In Pharmacology"},{"key":"10106_CR14","doi-asserted-by":"publisher","first-page":"1485033","DOI":"10.3389\/fcvm.2024.1485033","volume":"11","author":"JN Le","year":"2024","unstructured":"Le, J. N., Gasho, J. O., Peony, O., Singh, A., Silos, K. D., Kim, S., et al. (2024). Cardiac events and dynamic echocardiographic and electrocardiogram changes following osimertinib treatment in lung cancer. Front Cardiovasc Med, 11, 1485033.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10106_CR15","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","volume":"1","author":"K Anand","year":"2019","unstructured":"Anand, K., Ensor, J., Trachtenberg, B., & Bernicker, E. H. (2019). Osimertinib-Induced Cardiotoxicity: A Retrospective Review of the FDA Adverse Events Reporting System (FAERS). JACC CardioOncol, 1(2), 172\u2013178.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10106_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder, S., Sharma, U. C., & Pokharel, S. (2023). Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal Transduct Target Ther, 8(1), 262.","journal-title":"Signal Transduct Target Ther"},{"key":"10106_CR17","doi-asserted-by":"publisher","first-page":"1431023","DOI":"10.3389\/fonc.2024.1431023","volume":"14","author":"Y Wang","year":"2024","unstructured":"Wang, Y., Deng, X., Qiu, Q., & Wan, M. (2024). Risk factors of osimertinib-related cardiotoxicity in non-small cell lung cancer. Frontiers In Oncology, 14, 1431023.","journal-title":"Frontiers In Oncology"},{"issue":"9","key":"10106_CR18","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","volume":"74","author":"MJ Page","year":"2021","unstructured":"Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., et al. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol (Engl Ed), 74(9), 790\u2013799.","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10106_CR19","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., et al. (2017). AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Bmj, 358, j4008.","journal-title":"Bmj"},{"key":"10106_CR20","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne, J. A. C., Savovi\u0107, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., et al. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. Bmj, 366, l4898.","journal-title":"Bmj"},{"key":"10106_CR21","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne, J. A., Hern\u00e1n, M. A., Reeves, B. C., Savovi\u0107, J., Berkman, N. D., Viswanathan, M., et al. (2016). ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. Bmj, 355, i4919.","journal-title":"Bmj"},{"issue":"1","key":"10106_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness, L. A., & Higgins, J. P. T. (2021). Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods, 12(1), 55\u201361.","journal-title":"Res Synth Methods"},{"key":"10106_CR23","unstructured":"Page, M. J. H. J., & Sterne, J. A. C. (2024). In J. P. T. J. Higgins, J. Chandler, M. Cumpston, T. Li, & M. J. Page (Eds.), Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis. Cochrane."},{"issue":"4","key":"10106_CR24","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.20.01171","volume":"39","author":"MS Ewer","year":"2021","unstructured":"Ewer, M. S., Tekumalla, S. H., Walding, A., & Atuah, K. N. (2021). Cardiac Safety of Osimertinib: A Review of Data. Journal Of Clinical Oncology, 39(4), 328\u2013337.","journal-title":"Journal Of Clinical Oncology"},{"issue":"12","key":"10106_CR25","doi-asserted-by":"publisher","first-page":"e2448364","DOI":"10.1001\/jamanetworkopen.2024.48364","volume":"7","author":"C-Y Lin","year":"2024","unstructured":"Lin, C-Y., Chang, W-T., Su, P-L., Kuo, C-W., Yang, J., Lin, C-C., et al. (2024). Cardiac Events and Survival in Patients With EGFR-Mutant Non\u2013Small Cell Lung Cancer Treated With Osimertinib. JAMA Network Open, 7(12), e2448364\u2013e.","journal-title":"JAMA Network Open"},{"key":"10106_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2017.12.011","volume":"91","author":"M Schiefer","year":"2018","unstructured":"Schiefer, M., Hendriks, L. E. L., Dinh, T., Lalji, U., & Dingemans, A. C. (2018). Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring. European Journal Of Cancer, 91, 92\u201398.","journal-title":"European Journal Of Cancer"},{"key":"10106_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.lungcan.2020.10.021","volume":"153","author":"K Kunimasa","year":"2021","unstructured":"Kunimasa, K., Oka, T., Hara, S., Yamada, N., Oizumi, S., Miyashita, Y., et al. (2021). Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction. Lung Cancer, 153, 186\u2013192.","journal-title":"Lung Cancer"},{"issue":"1","key":"10106_CR28","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jaccao.2020.01.003","volume":"2","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo, A. J., Costa, D. B., Sabe, M. A., & Asnani, A. (2020). Heart Failure Associated With the Epidermal Growth Factor Receptor Inhibitor Osimertinib. JACC CardioOncol, 2(1), 119\u2013122.","journal-title":"JACC CardioOncol"},{"key":"10106_CR29","doi-asserted-by":"crossref","unstructured":"Mercurio, V., Agnetti, G., Pagliaro, P., & Tocchetti, C. G. (2019). Molecular Mechanisms of Cardiovascular Damage Induced by Anti-HER-2 Therapies. In A. Russo, G. Novo, P. Lancellotti, A. Giordano, & F. J. Pinto (Eds.), Cardiovascular Complications in Cancer Therapy (pp. 15\u201319). Springer International Publishing.","DOI":"10.1007\/978-3-319-93402-0_3"},{"key":"10106_CR30","doi-asserted-by":"publisher","first-page":"945206","DOI":"10.3389\/fphar.2022.945206","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang, Y., Wei, J., Zhang, P., Zhang, X., Wang, Y., Chen, W., et al. (2022). Neuregulin-1, a potential therapeutic target for cardiac repair. Frontiers In Pharmacology, 13, 945206.","journal-title":"Frontiers In Pharmacology"},{"issue":"7","key":"10106_CR31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4330\/wjc.v6.i7.653","volume":"6","author":"C Vasti","year":"2014","unstructured":"Vasti, C., & Hertig, C. M. (2014). Neuregulin-1\/erbB activities with focus on the susceptibility of the heart to anthracyclines. World Journal Of Cardiology, 6(7), 653\u2013662.","journal-title":"World Journal Of Cardiology"},{"issue":"1","key":"10106_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2020.02.003","volume":"2","author":"K Kunimasa","year":"2020","unstructured":"Kunimasa, K., Kamada, R., Oka, T., Oboshi, M., Kimura, M., Inoue, T., et al. (2020). Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib. JACC CardioOncol, 2(1), 1\u201310.","journal-title":"JACC CardioOncol"},{"key":"10106_CR33","doi-asserted-by":"crossref","unstructured":"Priantti, J. N., Fujiwara, Y., Moraes FCAd, Michelon, I., Castro, C., Leighl, N. B. (2024). Safety and Efficacy of Osimertinib in Patients With Non\u2013Small-Cell Lung Cancer and Uncommon Tumoral Epidermal Growth Factor Receptor Mutations: A Systematic Review and Single-Arm Meta-Analysis. JCO Precision Oncology. (8):e2400331.","DOI":"10.1200\/PO.24.00331"},{"key":"10106_CR34","doi-asserted-by":"publisher","first-page":"1177003","DOI":"10.3389\/fphar.2023.1177003","volume":"14","author":"P Li","year":"2023","unstructured":"Li, P., Tian, X., Wang, G., Jiang, E., Li, Y., & Hao, G. (2023). Acute osimertinib exposure induces electrocardiac changes by synchronously inhibiting the currents of cardiac ion channels. Frontiers In Pharmacology, 14, 1177003.","journal-title":"Frontiers In Pharmacology"},{"issue":"Suppl_1","key":"10106_CR35","doi-asserted-by":"publisher","first-page":"AP3110","DOI":"10.1161\/res.131.suppl_1.P3110","volume":"131","author":"AP Singh","year":"2022","unstructured":"Singh, A. P., Castro, C., Singh, A. S. C., Li, H., Sheffield, C. D., Roh, K., et al. (2022). Abstract P3110: Mechanism Of Cardiotoxicity Associated With Tyrosine Kinase Inhibitor Osimertinib. Circulation Research, 131(Suppl_1), AP3110\u2013AP.","journal-title":"Circulation Research"},{"issue":"1","key":"10106_CR36","first-page":"26","volume":"11","author":"AF Ozaki","year":"2025","unstructured":"Ozaki, A. F., Sayer, M., Hamano, H., Nagasaka, M., Lee, B. J., Doh, J., et al. (2025). Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy. Cardiooncology, 11(1), 26.","journal-title":"Cardiooncology"},{"issue":"1","key":"10106_CR37","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/jcb.27434","volume":"120","author":"Z Zhang","year":"2019","unstructured":"Zhang, Z., Zhang, M., Liu, H., & Yin, W. (2019). AZD9291 promotes autophagy and inhibits PI3K\/Akt pathway in NSCLC cancer cells. Journal Of Cellular Biochemistry, 120(1), 756\u2013767.","journal-title":"Journal Of Cellular Biochemistry"},{"issue":"9","key":"10106_CR38","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","volume":"35","author":"E Felip","year":"2024","unstructured":"Felip, E., Cho, B. C., Guti\u00e9rrez, V., Alip, A., Besse, B., Lu, S., et al. (2024). Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Annals Of Oncology, 35(9), 805\u2013816.","journal-title":"Annals Of Oncology"},{"key":"10106_CR39","doi-asserted-by":"crossref","unstructured":"Rocca, C., De Francesco, E. M., Pasqua, T., Granieri, M. C., De Bartolo, A., Gallo Cantafio, M. E. (2022). Mitochondrial Determinants of Anti-Cancer Drug-Induced Cardiotoxicity. Biomedicines. ;10(3).","DOI":"10.3390\/biomedicines10030520"},{"key":"10106_CR40","doi-asserted-by":"publisher","first-page":"175883592412647","DOI":"10.1177\/17588359241264721","volume":"16","author":"J-Y Byun","year":"2024","unstructured":"Byun, J-Y., Han, S., Liu, Y., & Park, C. (2024). Sex-specific risk of heart failure and acute myocardial infarction associated with osimertinib in older patients with non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 16, 17588359241264721.","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"6","key":"10106_CR41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s11523-025-01180-2","volume":"20","author":"Z Muhanna","year":"2025","unstructured":"Muhanna, Z., Al Zyoud, M., Issa, A., & Awidi, M. (2025). Cardiotoxicity profiles of osimertinib compared with other egfr tyrosine kinase inhibitors: a real-world comparative incidence analysis. Targeted Oncology, 20(6), 1015\u20131022. https:\/\/doi.org\/10.1007\/s11523-025-01180-2","journal-title":"Targeted Oncology"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12012-026-10106-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-026-10106-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:05:16Z","timestamp":1774076716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12012-026-10106-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10106"],"URL":"https:\/\/doi.org\/10.1007\/s12012-026-10106-x","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"value":"1530-7905","type":"print"},{"value":"1559-0259","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"During the preparation of this work, the authors used ChatGPT-5 to review the document\u2019s syntax and grammar. After using this tool\/service, the authors reviewed and edited the content as needed and took full responsibility for the content of the published article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration of Generative AI in Scientific Writing"}}],"article-number":"33"}}